BTW finally I've found the patent based on the paper in European Journal of Medicinal Chemistry paper that REALLY did a good job on detailing swapping the cyclohexyl moiety for a 4-thiane and the stereochemistry of derivatives that place a methyl side-chain at the spot where ketamine & MXE place the ketone moiety. It really explores the QSAR. Nor DAT data, sadly.
US6342511B1
Phencyclidine derivatives, preparation method and pharmaceutical compositions containing same.
I think it's important to remember that some of there replace the ketone moiety seen in of ketamine & MXE with a chiral methyl group. I've already mentioned that the cyclohexane can be replaced by a 4-thiane. MOST laws based on Markush structural definitions require a cyclohexyl. For that reason, I'm pretty sure that the thiane analogues of K & MXE would be the best targets to go for... You are changing the molecule the least you can so less chance of a nasty shock.
That said, I cannot find any examples of these whereas the 2-chloro-5-methoxy derivative of MXE (or MXM i.e. the methylamine homologue) are known, Anyone interested might be able to use the names in the patents to find papers that give some sort of explanation of why they issued a patent that covers so FEW novel compounds. I maintain that they found distinct clinical advantages over ketamine, thought they might have 'the next big thing' and secured their intellectual property rights. I COULD be utterly wrong but I've seen lots of patents and by that ear, most covered every damned homologue they could make.
Like why always -Cl? Not -F, --Br, -I or a pseudohalogen. I did post a decent reference that shows why the -Cl is the best option (I think) but it's open to some interpretation.